Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients.

  title={Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients.},
  author={Eric P. Brass and Sharon G. Adler and Kathy E. Sietsema and William R. Hiatt and Ahmed M. Orlando and Antonino Amato},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  volume={37 5},
  • E. BrassS. Adler A. Amato
  • Published 1 May 2001
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

These findings suggest that oral L-carnitine treatment improves immunological and cardiac markers in HD patients, and did not change the skeletal mass-related parameters during the 6-month follow-up.

The Effects of Carnitine Supplementation in Hemodialysis Patients

Regular L-carnitine supplementation on hemodialysis patients can improve their left ventricular ejection fraction and some parts of functionality.

The Effects of Oral L-Carnitine Supplementation on Physical Capacity and Lipid Metabolism in Chronic Hemodialysis Patients

L-carnitine supplementation might have some beneficial effects on the physical capacity of chronic hemodialysis patients due to the improvement of the lipid metabolism in the muscle.

Beneficial Effects of L-Carnitine in Dialysis Patients with Impaired Left Ventricular Function: An Observational Study

Eight months' therapy with carnitine appears to improve LV function and clinical status in dialysis patients with impaired LVF.

Influence of oral L-carnitine supplementation combined with physical training on exercise tolerance in patients with chronic obstructive pulmonary disease

Oral L-carnitine supplementation combined with physical training may improve tolerance to physical exertion in chronic obstructive pulmonary disease patients.

Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients.

After 24 weeks of i.v. carnitine therapy, SF-36 scores were improved and erythropoietin doses were reduced in hemodialysis patients, relative to the control group.

L carnitine in hemodialysis patients

The reports reviewed in this study have provided data suggesting that chronic renal failure and particularly hemodialysis patients can benefit from carnitine treatment in particular for renal anemia, insulin sensitivity, and protein catabolism.

Effect of l-carnitine supplementation on renal anemia in patients on hemodialysis: a meta-analysis

The present meta-analysis indicated that l-carnitine therapy significantly increased plasma l- carnitines concentrations, improved the response to ESA, decreased the required ESA doses in patients receiving hemodialysis, and maintained hemoglobin and hematocrit levels.

Dramatic Decrease of Carnitine Esters after Interruption of Exogenous Carnitine Supply in Hemodialysis Patients

A dramatic decrease in the level of FC, and in short- and medium-chain acylcarnitines (ACs) 44 h after the last dialysis is found, which results in dramatic decrease and reprofiling of carnitine esters even after the usual 44 h of interdialytic period.

Carnitine Replacement in End‐Stage Renal Disease and Hemodialysis

In patients with chronic renal failure, not yet undergoing hemodialysis (HD), plasma acylcarnitines accumulate in part due to a decreased renal clearance of esterified carnitine moieties, which may positively influence the nutritional status of HD patients by promoting a positive protein balance and by reducing insulin resistance and chronic inflammation.



Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.

Carnitine treatment was associated with a significant drop in pre-dialysis concentrations of serum urea nitrogen, creatinine and phosphorus, and no significant changes in any of these variables were noticed in the placebo group.

Carnitine metabolism during exercise in patients on chronic hemodialysis.

Patients on hemodialysis had a lower muscle total carnitine content than control subjects which was correlated to exercise performance, and the change in muscle short-chain acylcarnitines content with exercise was correlated with the increase in muscle lactate content.

Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients.

Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients.

It is suggested that prolonged low-dose L-carnitine treatment can improve dialysis-associated muscle symptoms by restoring carnitine tissue levels and washing out acyl moieties.

Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.

It is concluded that carnitine metabolism is altered in uremia, and in a randomly-selected hemodialysis population, L-carnitine injection at the dose of 20 mg/kg results in significant increases in blood (and perhaps tissue) carnite levels, but this is not associated with any major effects on lipid profiles.

Anemia and carnitine supplementation in hemodialyzed patients.

L-carnitine, in addition to iron supplementation, may have an effect on erythropoietin resistance and erythrocyte survival time in HD patients, and the rHuEPO requirement increased comparably in both L-c Carnitine- and placebo-treated patients during four more months.

A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure.

It is postulate that the rapid decline in plasma levels of carnitine caused by hemodialysis initiates unilateral transport of the compound from muscle to the plasma, thus depleting the skeletal muscle stores of carnItine, and the plasma and muscle Carnival levels remained in the normal range in patients on intermittent peritoneal dialysis and CAPD.

L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function.

The hypothesis that carnitine deficiency contributes to muscle and nerve dysfunction in patients on chronic haemodialysis is not supported.

Effect of intravenous L‐carnitine on carnitine homeostasis and fuel metabolism during exercise in humans

The skeletal muscle carnitine pool is segregated from dramatic changes in the plasma carnitines pool, and short‐term administration of carn itine has no significant effect on fuel metabolism during exercise in humans.